Glimepiride
- Generic Name
- Glimepiride
- Brand Names
- Duetact, Tandemact
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34N4O5S
- CAS Number
- 93479-97-1
- Unique Ingredient Identifier
- 6KY687524K
- Background
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure a...
- Indication
Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 44
- Registration Number
- NCT01565096
- Locations
- 🇩🇪
ikfe GmbH, Mainz, Germany
Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Marcus Borchert
- Target Recruit Count
- 40
- Registration Number
- NCT01547104
- Locations
- 🇩🇪
ikfe GmbH, Mainz, Rhineland-Palatinate, Germany
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 304
- Registration Number
- NCT01517373
- Locations
- 🇧🇬
MBAL Yulia Vrevska - Byala, Otdelenie po vatreshni bolesti, Byala, Bulgaria
🇧🇬DKTs Akta Medika, Kabinet po endokrinologia, Sevlievo, Bulgaria
🇨🇦Ocean West Research Clinic Inc., Surrey, British Columbia, Canada
Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 43
- Registration Number
- NCT01511692
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 145
- Registration Number
- NCT01511172
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Yaxley. Peterborough, United Kingdom
Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-01-13
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 196
- Registration Number
- NCT01509755
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Worksop, United Kingdom
Study of Metabolic and Haemodynamic Effects of Metformin and Glimepiride in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2012-01-12
- Last Posted Date
- 2012-01-16
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 20
- Registration Number
- NCT01509001
- Locations
- 🇧🇷
Clinical Hospital of São Paulo Medical School, são Paulo, SP, Brazil
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 431
- Registration Number
- NCT01494987
- Locations
- 🇺🇸
Clinical Research Advantage/Desert Clinical Research, LLC, Mesa, Arizona, United States
🇺🇸Desert Sun Clinical Research, LLC, Tucson, Arizona, United States
🇺🇸Southland Clinical Research Center, Inc., Fountain Valley, California, United States
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2454
- Registration Number
- NCT01481116
Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 538
- Registration Number
- NCT01459809
- Locations
- 🇹🇷
Investigational Site Number 792-002, Kutahya, Turkey
🇦🇪Investigational Site Number 784-001, Dubai, United Arab Emirates
🇪🇬Investigational Site Number 81802, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.